Poster: Genovis - Svar Collaboration on ADCC
Newsletter

Poster: Genovis - Svar Collaboration on ADCC

In a recent collaboration between Svar Life Science and Genovis, the effects of TransGLYCIT, a transglycosylation modifying enzyme that modifies human IgG1 to carry different glycoforms, on the elicit ADCC (Antibody-dependent Cellular Cytotoxicity) activity was evaluated using the iLite® ADCC Cell-based solutions.

The work was presented at the Antibody Engineering & Therapeutics conference in Amsterdam in 2022.

The poster "Fast and Efficient Evaluation of the Impact of Fc N-glycosylation on Antibody-dependent Cellular Cytotoxicity" presents data generated by using the transglycosylation workflow TransGLYCIT™ to successfully modify human IgG1 to carry either G0, G1, G2, or G2S2 glycoforms with or without core fucosylation before the ADCC activities were determined using iLite ADCC Reporter Gene Assay from Svar Life Science. 

Fill in the form to access the free poster